Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F18%3A00011975" target="_blank" >RIV/00023736:_____/18:00011975 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/18:00103231 RIV/61989592:15110/18:73587842 RIV/65269705:_____/18:00068643 RIV/00179906:_____/18:10386507
Result on the web
<a href="https://doi.org/10.1016/S1470-2045(18)30192-X" target="_blank" >https://doi.org/10.1016/S1470-2045(18)30192-X</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(18)30192-X" target="_blank" >10.1016/S1470-2045(18)30192-X</a>
Alternative languages
Result language
angličtina
Original language name
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Original language description
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. We aimed to define precise conditions for stopping treatment. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet oncology
ISSN
1470-2045
e-ISSN
—
Volume of the periodical
19
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
747-757
UT code for WoS article
000434153000041
EID of the result in the Scopus database
2-s2.0-85046637421